AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion (NCT04099966)
Allogeneic Stem Cell Transplantation for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion - NYMC 588
๐ฉบ Plain-English Summary (8th-Grade Level)
Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing ฮฑ/ฮฒ CD3+/CD19+ cell depletion. All other treatment is standard of care.
Who can join: Review the eligibility criteria below.
Location: New York Medical College โ Valhalla, New York
Age range: 1 Day to 30 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (1 Sites)
- New York Medical College โ Valhalla, New York
๐ Contact the Study Coordinator
Phone: (914) 594-2150
Email: mitchell_cairo@nymc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Leukemia
- Cytogenetic Studies in Acute Leukemia and Multiple Myeloma โ La Jolla, California
- ATG Plus PTCy vs ATG for CGVHD Prophylaxis โ Darlinghurst, New South Wales
- Cancer Stem Cells in Acute Leukemia โ Fargo, North Dakota
- A High Intensity Electronic Health Intervention for the Reduction of Learning Disparities in Childhood Cancer Survivors โ Duarte, California
- Prevention of Hospital Acquired Deconditioning in Hospitalized Acute Leukemia Patients โ Manhasset, New York
- A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies โ Duarte, California
Explore by condition: All Acute Leukemia clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.